Abstract |
Diltiazem alters human atrioventricular nodal properties in a dose and rate-dependent manner. Intravenous diltiazem is effective in converting supraventricular tachycardia to sinus rhythm. It may be a very useful drug for sustained control of heart rate in patients with rapid atrial fibrillation. The recommended intravenous dose is 0.25 mg/kg given over 2 mins followed by a maintenance infusion of 5 to 15 mg/h. Clinical data on the electrophysiological effects of oral diltiazem are limited. The oral form may be used as an alternative agent for the prophylaxis of recurrent supraventricular tachycardia.
|
Authors | D Roy |
Journal | The Canadian journal of cardiology
(Can J Cardiol)
1995 Jul-Aug
Vol. 11
Issue 7
Pg. 538-40
ISSN: 0828-282X [Print] England |
PMID | 7656189
(Publication Type: Clinical Trial, Comparative Study, Journal Article)
|
Chemical References |
|
Topics |
- Administration, Oral
- Diltiazem
(administration & dosage)
- Dose-Response Relationship, Drug
- Humans
- Injections, Intravenous
- Recurrence
- Retrospective Studies
- Tachycardia, Supraventricular
(drug therapy, prevention & control)
- Verapamil
(administration & dosage)
|